Featured Tickers:
Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Travere Therapeutics, Inc., ADMA Biologics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.
Read on to learn how Travere Therapeutics, Inc., ADMA Biologics and Inc. compare based on key financial metrics to determine which better meets your investment needs.
About Travere Therapeutics, Inc., ADMA Biologics and Inc.
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company’s products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Latest Biotechnology and Travere Therapeutics, Inc., ADMA Biologics, Inc. Stock News
As of September 10, 2025, Travere Therapeutics, Inc. had a $2.4 billion market capitalization, compared to the Biotechnology median of $167.6 million. Travere Therapeutics, Inc.’s stock is up 56.8% in 2025, up 29.1% in the previous five trading days and up 148.73% in the past year.
Currently, Travere Therapeutics, Inc. does not have a price-earnings ratio. Travere Therapeutics, Inc.’s trailing 12-month revenue is $333.9 million with a -50.6% net profit margin. Year-over-year quarterly sales growth most recently was 111.5%. Analysts expect adjusted earnings to reach $-0.184 per share for the current fiscal year. Travere Therapeutics, Inc. does not currently pay a dividend.
As of September 10, 2025, ADMA Biologics, Inc. had a $3.8 billion market cap, putting it in the 66th percentile of all stocks. ADMA Biologics, Inc.’s stock is down 8.1% in 2025, down 6.8% in the previous five trading days and down 3.08% in the past year.
Currently, ADMA Biologics, Inc.’s price-earnings ratio is 18.7. ADMA Biologics, Inc.’s trailing 12-month revenue is $474.2 million with a 44.1% net profit margin. Year-over-year quarterly sales growth most recently was 13.8%. Analysts expect adjusted earnings to reach $0.565 per share for the current fiscal year. ADMA Biologics, Inc. does not currently pay a dividend.
How We Compare Travere Therapeutics, Inc., ADMA Biologics and Inc. Stock Grades
Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.
AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Travere Therapeutics, Inc., ADMA Biologics and Inc.’s stock grades to see how they measure up against one another.
Learn more about A+ Investor here!
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions